



The Role of Affect-Related Neuropeptides in Health and Disease

Guest Editors:

Dr. Anna Brancato

Department of Health
Promotion, Mother and Child
Care, Internal Medicine and
Medical Specialties of Excellence,
University of Palermo, Palermo,
Italy

Prof. Carla Cannizzaro

Department of Biomedicine,
Neuroscience and Advanced
Diagnostics, University of
Palermo, Palermo, Italy

Deadline for manuscript
submissions:

closed (31 August 2022)

Message from the Guest Editors

This Special Issue aims at gathering recent advances in the role of affect-related neuropeptides, including neuropeptide Y, oxytocin, corticotropin-releasing factor, orexin, cholecystokinin, calcitonin gene-related peptide, endogenous opioids, and brain-derived neurotrophic factor in the context of reward and aversion.

Contributions addressing neuropeptides' involvement in maladaptive affective states associated with pathological conditions, such as depression, anxiety, addiction, and eating disorders, are also of interest.

As such, neuropeptides hold great promise for the identification of new biomarkers for more effective diagnosis, besides representing exciting candidates for novel therapeutics.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)